Objective: To compile the literature related to the treatment of qi deficiency and blood stasis in the recovery period of cerebral infarction in Chinese medicine in the past 20 years,and to investigate the drug use pattern of qi deficiency and blood stasis in the recovery period of cerebral infarction in Chinese medicine by using data mining technology,and to explore the mechanism of action of core drugs with the help of network pharmacology.Data and methods:We searched the relevant literature on Chinese medicine for the treatment of Qi deficiency and blood stasis in the recovery period of cerebral infarction from China Knowledge Network,Wanfang and Wipu databases until December 31,2022,and obtained the prescriptions from the literature.The collected prescriptions were entered,standardized and summarized using Microsoft Excel,and frequency statistics were performed for Chinese medicine,four qi,five flavors and drug attribution,The active ingredients and targets of the core drugs were obtained from the TCMSP database,and the disease targets in the recovery phase of cerebral infarction were obtained from the Gene Cards and TTD databases.The PPI network was constructed with the help of String database and Cytoscape3.9.1 software to obtain the core targets,and the GO functional enrichment analysis and KEGG pathway analysis were performed on the microbial platform to obtain the mechanism of action of the core drugs in the recovery phase of cerebral infarction.Results:1.Through the frequency analysis of 103 Chinese medicines in 117 prescriptions(total 1256medicines),the high frequency medicines(>30)were: Huang Qi,Chuan Xiong,Angelica sinensis,Di Long,Hong Hua,Red Peony,Tao Ren,Dan Shen and Leech.2.Distribution of properties,tastes and meridians: the top three properties were warm,flat and cold;the top three tastes were sweet,pungent and bitter;the top three meridians were liver meridians,followed by heart,spleen,lung and kidney meridians;the top three categories of frequency of use were blood-stasis activators,deficiency tonics and heat-clearing drugs.3.The analysis of the association rules showed that,whether in terms of strong linkage or support,the most commonly used medicine and commonly used drug combination was Huangqi-Chuanxiong-Danggui combination.4.The top 5 core targets are JUN,AKT1,IL6,VEGFA and CASP3,which have various pharmacological activities,such as regulation of immune function,anti-coagulation and antioxidant damage,and reduction of blood glucose level.Akt signaling pathway,IL-17 signaling pathway,AGE-RAGE signaling pathway in diabetic complications,TNF signaling pathway,etc.It has been shown to inhibit apoptosis,anti-inflammatory,pro-vascular growth and cell proliferation,anti-atherosclerosis and lipid-lowering effects in the treatment of cerebral infarction.Conclusions:1.Through the frequency analysis of 103 Chinese medicines in 117 prescriptions(total 1256medicines),the high frequency medicines(>30)were: Huang Qi,Chuan Xiong,Angelica sinensis,Di Long,Hong Hua,Red Peony,Tao Ren,Dan Shen and Leech.2.Distribution of properties,tastes and meridians: the top three properties were warm,flat and cold;the top three tastes were sweet,pungent and bitter;the top three meridians were liver meridians,followed by heart,spleen,lung and kidney meridians;the top three categories of frequency of use were blood-stasis activators,deficiency tonics and heat-clearing drugs.The analysis of the association rules showed that,whether in terms of strong linkage or support,the most commonly used medicine and commonly used drug combination was Huangqi-Chuanxiong-Danggui combination.3.The top 5 core targets are JUN,AKT1,IL6,VEGFA and CASP3,which have various pharmacological activities,such as regulation of immune function,anti-coagulation and antioxidant damage,and reduction of blood glucose level.Akt signaling pathway,IL-17 signaling pathway,AGE-RAGE signaling pathway in diabetic complications,TNF signaling pathway,etc.It has been shown to inhibit apoptosis,anti-inflammatory,pro-vascular growth and cell proliferation,anti-atherosclerosis and lipid-lowering effects in the treatment of cerebral infarction. |